Literature DB >> 31101967

Outcomes of ureteroscopy for stone disease in anomalous kidneys: a systematic review.

Lisa Lavan1, Thomas Herrmann2, Christopher Netsch3, Benedikt Becker3, Bhaskar K Somani4,5.   

Abstract

INTRODUCTION: Treatment of stone disease in anomalous kidneys can be challenging. As ureteroscopy (URS) has advanced, the number of studies reporting on outcomes of URS for stone disease in anomalous kidneys has increased. Our objective was to perform a systematic review of the literature to evaluate the outcomes of URS for stone disease in this group of patients.
METHODS: A Cochrane style review was performed in accordance with the PRISMA guidelines using Medline, EMBASE, CINAHL, Cochrane Library, Scopus and individual urologic journals for all English language articles between inception and June 2018.
RESULTS: Fourteen papers (413 patients) with a mean age of 43 years and a male to female ratio of 285:128 were included. The underlying renal anomaly was horseshoe kidney (n = 204), ectopic kidney (n = 117), malrotation (n = 86), cross fused ectopia (n = 2) and others (n = 2). With a mean stone size of 16 mm (range 2-35 mm), the majority of stones were in the lower pole (n = 143, 34.6%) or renal pelvis (n = 128, 31.0%), with 18.9% (n = 78) having stones in multiple locations. Treatment modality included the use of flexible ureteroscope in 90% of patients and ureteral access sheath used in 11 studies. With a mean operative time of 61.3 min (range 14-185 min), the initial and final SFR was 76.6% (n = 322) and 82.3% (n = 340), respectively. The overall complication rate was 17.2% (n = 71), of which 14.8% were Clavien I/II and the remaining 2.4% were Clavien ≥ III complications.
CONCLUSION: Although ureteroscopy in patients with anomalous kidneys can be technically challenging, advancements in endourological techniques have made it a safe and effective procedure. In these patients the stone-free rates are good with a low risk of major complications.

Entities:  

Keywords:  Ectopic kidney; Horseshoe kidney; Malrotation; Pelvic; RIRS; Renal anomaly; Ureteroscopy; Urolithiasis

Year:  2019        PMID: 31101967      PMCID: PMC7190593          DOI: 10.1007/s00345-019-02810-x

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


Introduction

Anomalous kidneys arise from different abnormalities in the embryological development [1]. These may relate to abnormal ascent, fusion, rotation or a combination of these. Whilst the commonest renal anomaly is the horseshoe kidney (HSK) with an incidence of 1 in 400, ectopic kidneys (EK) are reported with an incidence of 1 in 3000, with the incidence of isolated malrotation (MR) less widely reported [1]. These anatomical anomalies not only lead to compromised renal drainage, but also increase the risk of urolithiasis [2-4]. Endourological management is challenging due to these abnormalities leading to difficulties accessing the stone [2]. Treatment such as shockwave lithotripsy (SWL) and percutaneous nephrolithotomy (PCNL) are well described in anomalous kidneys, but can be technically challenging, with success rates often reported to be lower than those in normal kidneys [3-8]. Advances in technology and technique have allowed a broadening of indications for flexible ureterorenoscopy (FURS). The development of smaller calibre ureteroscopes with their increased deflection capability, along with holmium laser fibres and other adjuncts, make FURS an attractive treatment modality for challenging intrarenal anatomy [9]. Recently, the number of studies reporting on the outcomes of ureteroscopy (URS) in anomalous kidneys has increased. However, endoscopic access can be challenging, with complications and stone-free rates (SFR) that are variable across the reported studies. This article aims to review and summarise the efficacy and safety of FURS for urolithiasis in anomalous kidneys.

Methods

Search strategy and study selection

Our systematic review was performed according to Cochrane review guidelines and the preferred reporting items for systematic reviews and meta-analysis (PRISMA) standards [10]. A literature search was conducted using MEDLINE, EMBASE, CINAHL, Scopus, the Cochrane Library and individual urology journals for all English language articles. Search terms used included the following: ‘ureteroscopy’, ‘ureterorenoscopy’, ‘retrograde intrarenal surgery’, ‘RIRS’, ‘URS’, ‘ureteroscopy’, ‘ureteroscopic management’, ‘urolithiasis’, ‘anomalous kidney’, ‘malrotation’, ‘horseshoe kidney’, ‘ectopic kidney’, ‘calculi’ and ‘stone’. The references of identified studies were examined to identify any further potential studies for inclusion. Boolean operators (AND, OR) were used to refine the search. The study period was from inception of databases to June 2018 (Fig. 1).
Fig. 1

PRISMA flowchart of the included studies

PRISMA flowchart of the included studies A cutoff of five patients was set to include studies from centres with minimum relevant endourological experience in managing stones in anomalous kidneys. All original studies were included and where more than one article was available, the study with the longest follow-up was included. Two reviewers (LL and BS) not involved in the original work identified all the studies and those that appeared to fit the inclusion criteria were included for full review. The studies were selected independently, and all discrepancies resolved by mutual consensus.

Inclusion criteria

All English language articles reporting on the outcomes of ureteroscopic management of urolithiasis in anomalous kidneys. Patients of all age groups.

Exclusion criteria

Case reports, review articles and case series with less than five patients. Simulation, animal and laboratory studies. Studies with non-urolithiasis condition or use of treatments other than URS.

Data extraction and analysis

Of the eligible studies, data were extracted for patient and stone demographics, previous endourological procedures, imaging modality used, operative technique, including laser fibre size and settings used, SFR including stone-free definition, need for further procedures, follow-up protocol and complications, using Clavien–Dindo classification [11]. Data was collated using Microsoft Excel (version 12.2.4). Quality of evidence was assessed, and bias was analysed using the GRADE assessment tool [12].

Results

After initial identification and screening of 217 articles, 20 abstracts were further evaluated. Of these, on screening of abstracts and full paper, 14 full text articles were included in the final review (Fig. 1). In total, 413 patients with a mean age of 43 years (range 1–78 years) and a male to female ratio of 285:128 were included. The underlying renal anomaly was HSK (n = 204), EK (n = 117), MR (n = 86), cross fused ectopia (n = 2) and others (n = 4). The majority of these studies (n = 13) were retrospective with just one prospective study [26] (Table 1).
Table 1

Patient demographics and case mix of the included studies

ReferencesStudy designTotal patientsHSKEKMROtherMean age, years (range)MaleFemale
Weizer et al. [13]Retrospective8440050.6 (35–69)62
Molimard et al. [14]Retrospective171700034.7 (16–52)143
Atis et al. [15]Retrospective202000040.9 (NR)128
Bozkurt et al. [16]Retrospective260260041.1 (7–72)197
Oḡuz et al. [17]Retrospective240024039.8 (1–71)186
Urgulu et al. [18]Retrospective253114539.4 (NR)178
Ding et al. [19]Retrospective161600042.9 (22–66)133
Blackburn et al. [20]Retrospective202000048.1 (29–78)137
Gokce et al. [21]Retrospective2323000042.5 (16–78)185
Bansal et al. [22]Retrospective99000NR72
Ergin et al. [23]Retrospective101363332039.0 (1–72)6833
Singh et al. [24]Retrospective255145138.28 (NR)178
Legemate et al. [25]Retrospective86432716049.2 (NR)5729
Astolfi et al. [26]Prospective13805046.1 (NR)67
Total41320411786643.4285128

HSK horseshoe kidney, EK ectopic kidney, MR malrotation

Patient demographics and case mix of the included studies HSK horseshoe kidney, EK ectopic kidney, MR malrotation The mean stone size reported from 12 studies was 16 mm (range 2–35 mm). In the majority of patients the stone location was in the lower pole (n = 143, 34.6%) or renal pelvis (n = 128, 31%), with 18.9% (n = 78) having stones in multiple locations (Table 2). Pre-operative imaging included a combination of modalities [intravenous urogram (IVU), plain abdominal KUB XR (AXR), ultrasound scan (USS) or CT scan], although two studies used non-contrast computerised tomography (NCCT) as the only imaging modality [14, 24] (Table 3). A total of 126 (30.5%) patients had a history of previous endourological intervention [13–19, 22, 25] (Table 3).
Table 2

Stone size and location in the included studies

ReferencesStone size mean (mm)/[mm2]Stone size range (mm)/[mm2]Single stoneMultiple stonesStone position, lower poleStone position, midpoleStone position, upper poleStone position, renal pelvisStone position, mixedStone position, upper ureter
Weizer et al. [13]143–20534025(3)0
Molimard et al. [14]167–357107100
Atis et al. [15]17.8± 4.55159745(5)0
Bozkurt et al. [16]1710–282157001450
Oḡuz et al. [17]13.55–302409321000
Urgulu et al. [18][194.7][85–393]19614477(6)0
Ding et al. [19]29.817–424121102120
Blackburn et al. [20]8.42–2517310NRNRNRNR0
Gokce et al. [21]17.16–251496001700
Bansal et al. [22]15.4NR631200000
Ergin et al. [23]16.1NRNRNR35161445(9)0
Singh et al. [24]14.7± 4.1 mm1510118511(12)2
Legemate et al. [25][84][4–117]7016183231513
Astolfi et al. [26]12.26–22121720210
Total [mean][16.0]2199314344361287815
Table 3

Data on pre-operative variables

ReferencesPre-operative imagingPre-operative urine MC and SPeri-operative antibioticsPre-operative stentPrevious SWLPrevious PCNLPrevious open procedurePrevious URS> 1 previous procedure
Weizer et al. [13]IVU or NCCTNRNR1 12.5%)60101
Molimard et al. [14]NCCTYesNR4 (23.5%)8423NR
Atis et al. [15]AXR and IVU or USYesYes044404
Bozkurt et al. [16]NCCT or IVUYesNRNR90100
Oḡuz et al. [17]AXR, IVU, US or NCCTYesYesNR120040
Urgulu et al. [18]IVU and CTYesNRNR7221NR
Ding et al. [19]AXR and IVU or NCCTNRYesNR71001
Blackburn et al. [20]NRNRNRNRNRNRNRNRNR
Gokce et al. [21]AXR and USS or NNCTYesYesNRNRNRNRNRNR
Bansal et al. [22]AXR, IVU, USS or NCCTNRYesNR25000
Ergin et al. [23]IVU, USS or NCCTYesNRNRNRNRNRNRNR
Singh et al. [24]CTUYesNR5 (20%)NRNRNRNRNR
Legemate et al. [25]AXR, IVU or NCCTYesYes18 (24.7%)2012015NR
Astolfi et al. [26]AXR or NCCTNRNR11 (84.6%)NRNRNRNRNR
Total40 (29.4%)75 (59.2%)28 (22.2%)10 (7.9%)23 (18.3%)

AXR plain abdominal X-ray, IVU intravenous urogram, USS ultrasound scan, NCCT non-contrast computerised tomography, CTU computerised tomography urogram, NR not reported, SWL shockwave lithotripsy, PCNL percutaneous nephrolithotomy, URS ureteroscopy

Stone size and location in the included studies Data on pre-operative variables AXR plain abdominal X-ray, IVU intravenous urogram, USS ultrasound scan, NCCT non-contrast computerised tomography, CTU computerised tomography urogram, NR not reported, SWL shockwave lithotripsy, PCNL percutaneous nephrolithotomy, URS ureteroscopy While semirigid URS was used in 41 (10%) cases, FURS was used in 90% of cases. Of the reported studies, a pre-operative stent was reported in 26.4% (range 12.4–84.6%, 40/136 patients) [13–15, 24–26]. Placement of ureteral access sheath (UAS) was reported in 11 studies [13–19, 21, 22, 24, 25]. The success rates for UAS placement varied from 50 to 100% across studies (Table 4). Fragmentation device was reported in 13 studies, of which 12 used holmium laser lithotripsy for all of their patients. A range of fibre sizes and energy settings was reported. The mean operative time was 61.3 min (range 14–185 min). While six studies report a post-operative stent placement in all of their patients [13, 14, 19, 21, 22, 26], in the remaining studies this varied from 46.2 to 84% and was at the surgeon’s discretion [15–17, 23–25]. The mean hospital stay across studies was 1.7 days (range 0.5–9 days) (Table 4).
Table 4

Intraoperative and post-operative data from included studies

ReferencesAnaesthesiaProcedureHolmium laserFibre size (μm)Energy setting (J)Energy setting (Hz)Access sheath usedPost-operative stentMean operative time, min (range)Length of stay, days (range)
Weizer et al. [13]NRFURSYes2000.6–1.06–104 (50%)8 (100%)126 (90–185)NR
Molimard et al. [14]GAFURSYes150 or 3650.8–1.28–1217 (100%)17 (100%)92 (45–140)1.7 (1–3)
Atis et al. [15]GASRU and FURSYes2730.6–1.05–1020 (100%)15 (75%)40.51.4
Bozkurt et al. [16]GAFURSYes2000.810012 (46%.52.1 (30–120)2.7 (1–9)
Oḡuz et al. [17]GASRU and FURSYes273NRNR20 (83%)17 (71%)48.7 (18–135)1.5 (1–5)
Urgulu et al. [18]GAFURSYes200 or 273NRNR18 (72%)NR48 (14–115)NR
Ding et al. [19]SpinalSRU and FURSYes2000.8–1.210–1516 (100%)16 (100%)92 (14–127)0.8 (0–3)
Blackburn et al. [20]NRNRNRNRNRNRNRNRNRNR
Gokce et al. [21]GAFURSYesNR0.8–1.28–1223 (100%)23 (100%)NR1.8 (1–3)
Bansal et al. [22]GAFURSYes2000.6–0.810–159 (100%)9 (100%)84.2NR
Ergin et al. [23]GASRU and FURSYes170 or 200NRNRNR50 (50%)47.11.9
Singh et al. [24]GAFURSYes200 or 3650.5–1.010–1525 (100%)21 (84%)742.48
Legemate et al. [25]NR

SRU alone 47.7%

FURS 32.6%

Combination 17.4%

57%NRNRNR29 (71%)71 (84%)58 (30–120)1 (0.5–5)
Astolfi et al. [26]GASRU and FURSYes200 or 273NRNRNR13 (100%)NRNR

GA general anaesthetic, SRU semirigid ureteroscopy, FURS flexible ureterorenoscopy, NR not reported

Intraoperative and post-operative data from included studies SRU alone 47.7% FURS 32.6% Combination 17.4% GA general anaesthetic, SRU semirigid ureteroscopy, FURS flexible ureterorenoscopy, NR not reported With no universal definition of SFR between studies, their follow-up imaging also varied and sometimes even within each study. While ten studies did the post-operative imaging after 4 weeks [13–19, 21, 22, 24], one study did it after 3 months [26] and the remaining three did not mention the time interval for follow-up imaging [20, 23, 25] (Table 5).
Table 5

Post-operative outcomes from included studies

ReferencesDefinition of successPost-op imaging modalityImaging time interval (weeks)Overall success rate (%)Success after single procedureAuxiliary procedures requiredReadmissionComplications Clavien I–IIComplications Clavien ≥ III
Weizer et al. [13]Stone freeAXR and IVU or NCCT4–1275.075.00NR00
Molimard et al. [14]RF ≤ 3 mmAXR and USS or NCCT4 - 688.253.07 URS180
Atis et al. [15]RF < 4 mmIVU and USS (NCCT if RF)480.070.06 SWL050
Bozkurt et al. [16]RF ≤ 2 mmNCCT484.7NRNRNR32
Oḡuz et al. [17]RF ≤ 3 mmIVU and USS (NCCT if RF)483.375.0

1 SWL

1 URS

1112
Urgulu et al. [18]Complete clearanceNCCT488.064.0

6 URS

3 SWL

NR30
Ding et al. [19]Not definedAXR and USS487.562.56 URSNR30
Blackburn et al. [20]RF < 4 mmAXR or CTNR84.0NRNRNRNRNR
Gokce et al. [21]RF < 3 mmAXR and/or USS/NCCT2 - 673.9NRNR040
Bansal et al. [22]RF ≤ 4 mmAXR and USS or NCCT488.967.73 URS140
Ergin et al. [23]RF < 3 mmNRNR76.9NR8 URSNR122
Singh et al. [24]RF < 2 mmAXR and USS488.072.03 PCNLNR51
Legemate et al. [25]RF ≤ 1 mmAXR and USS or NCCTNR58.3NR151223
Astolfi et al. [26]RF < 2 mmAXR or NCCT1275.0NRNR010
Overall82.3% (n = 340)76.6% (n = 322)181561 (14.8%)10 (2.4%)

RF residual fragments, AXR plain abdominal X-ray, IVU intravenous urogram, USS ultrasound scan, NCCT non-contrast computed tomogram, URS ureteroscopy, SWL shockwave lithotripsy, PCNL percutaneous nephrolithotomy

Post-operative outcomes from included studies 1 SWL 1 URS 6 URS 3 SWL RF residual fragments, AXR plain abdominal X-ray, IVU intravenous urogram, USS ultrasound scan, NCCT non-contrast computed tomogram, URS ureteroscopy, SWL shockwave lithotripsy, PCNL percutaneous nephrolithotomy The initial and final SFR was 76.6% (n = 322) and 82.3% (n = 340), respectively, with 18 patients needing ancillary treatment which was a mix of repeat URS or SWL or PCNL (Table 5). Three studies reported the demographics and outcomes of HSK, EK and MR individually [18, 23, 25] (Table 6).
Table 6

Studies reporting on outcomes for individual data for HSK, EK and MR

Mean stone burden [range]Percentage of lower pole stones (%)Success after single procedureOverall success (%)
Urgulu et al. [18]HSK (n = 3)253 mm2 ± 103.750.066.7%66.7
EK (n = 13)

237.7 mm2 ± 94.4 (lumbar)

168.8 mm2 ± 101.7 (pelvic)

57.1

33.3

61.5%100
MR (n = 4)201.3 mm2 ± 109.575.0100%100
Ergin et al. [23]HSK (n = 36)17.8 mm ± 4.530.6NR72.2
EK (n = 33)17.0 mm ± 5.136.4NR83.6
MR (n = 32)13.4 mm ± 3.737.5NR75.0
Legemate et al. [25]HSK (n = 23)70 mm2 [46–134]52.1NR77.3
EK (n = 10)120 mm2 [79–263]30.0NR20.0
MR (n = 8)62 mm2 [0–148]37.5NR71.4

HSK horseshoe kidney, EK ectopic kidney, MR malrotation

Studies reporting on outcomes for individual data for HSK, EK and MR 237.7 mm2 ± 94.4 (lumbar) 168.8 mm2 ± 101.7 (pelvic) 57.1 33.3 HSK horseshoe kidney, EK ectopic kidney, MR malrotation Overall, 71 (17.2%) complications were reported of which 61 (14.8%) were Clavien–Dindo ≤ II, and 10 (2.4%) were Clavien–Dindo ≥ III. The Clavien I/II complications included stent symptoms (n = 7), haematuria (n = 15), post-operative pyrexia (n = 21) and confirmed urinary tract infection (n = 6). Of the nine Clavien III complications, surgical intervention for ureteric colic accounted for seven of these and the remaining two interventions were not specified. The single Clavien IV complication occurred in one of the largest studies [25], where an obese patient with a large stone (262 mm [2]) and prolonged operating time (121 min) developed sepsis with acute renal failure. This patient was treated with percutaneous nephrostomy, antibiotics and intensive care support (ICU) (Tables 5, 7).
Table 7

Complications graded as per Clavien–Dindo classification

ReferencesClavien I–IIClavien ≥ III
Weizer et al. [13]NoneNone
Molimard et al. [14]

Stent symptoms n = 6

Haematuria n = 1

Pyelonephritis n = 1

None
Atis et al. [15]

Post-operative pyrexia n = 3

Haematuria n = 2

None
Bozkurt et al. [16]

Post-operative pyrexia n = 1

Haematuria n = 1

Urinary tract infection n = 1

Ureteric colic requiring JJ stent n = 2
Oḡuz et al. [17]

Post-operative pyrexia n = 2

Ureteric colic (conservative management) n = 9

Ureteric colic requiring surgical intervention n = 2
Urgulu et al. [18]

Urosepsis n = 1

Pyelonephritis n = 1

Ureteric colic (conservative management) n = 1

None
Ding et al. [19]Post-operative pyrexia n = 3None
Blackburn et al. [20]Complications not reportedComplications not reported
Gokce et al. [21]

Haematuria n = 3

Post-operative pyrexia n = 1

None
Bansal et al. [22]

Post-operative pyrexia n = 2

Stent symptoms n = 1

Pyelonephritis n = 1

None
Ergin et al. [23]

Haematuria n = 7

Post-operative pyrexia n = 5

Ureteric colic requiring JJ stent n = 2
Singh et al. [24]

Post-operative pyrexia n = 3

Urinary tract infection n = 2

Ureteric colic requiring JJ stent n = 1
Legemate et al. [25]

Post-operative pyrexia n = 1

Urosepsis n = 1

IIIa not defined n = 1

IIIb not defined n = 1

IVa Urosepsis requiring nephrostomy and ITU support n = 1

Astolfi et al. [26]Haematuria n = 1None
Complications graded as per Clavien–Dindo classification Stent symptoms n = 6 Haematuria n = 1 Pyelonephritis n = 1 Post-operative pyrexia n = 3 Haematuria n = 2 Post-operative pyrexia n = 1 Haematuria n = 1 Urinary tract infection n = 1 Post-operative pyrexia n = 2 Ureteric colic (conservative management) n = 9 Urosepsis n = 1 Pyelonephritis n = 1 Ureteric colic (conservative management) n = 1 Haematuria n = 3 Post-operative pyrexia n = 1 Post-operative pyrexia n = 2 Stent symptoms n = 1 Pyelonephritis n = 1 Haematuria n = 7 Post-operative pyrexia n = 5 Post-operative pyrexia n = 3 Urinary tract infection n = 2 Post-operative pyrexia n = 1 Urosepsis n = 1 IIIa not defined n = 1 IIIb not defined n = 1 IVa Urosepsis requiring nephrostomy and ITU support n = 1

Quality assessment of the included studies

Of the 14 studies included, there was only one prospective study [26], with all others based on retrospective observational case series. The overall quality of evidence was graded as ‘very low’ and risk of bias ‘very high’ as detailed in Fig. 2.
Fig. 2

Risk of bias analysis

Risk of bias analysis

Discussion

Meaning of the study

The incidence of anomalous kidneys is relatively low with mostly small retrospective studies reporting on the outcomes of surgery for urolithiasis in these patients. However, in experienced hands ureteroscopy can offer good SFR with a low risk of major (Clavien ≥ III) complications even for large stones. It seems that over the last decade, there have been more studies reporting on the outcomes of FURS in this setting.

Comparison of studies reporting on FURS for renal anomalies

Weizer et al. [13] reported the first series on ureteroscopic management of renal calculi in eight patients with anomalous kidneys (four HSK, four EK) with stones up to 2 cm. They report the use of UAS to straighten the tortuous ureter, relocation of stone to a more favourable location and extraction of fragments leading to an overall success rate of 75% with none of the patient requiring auxiliary treatment. Molimard et al. [14] reviewed the outcomes of FURS and holmium lasertripsy in 17 patients with horseshoe kidneys. They used UAS in all patients with automatic flow irrigation at 100 cm H2O to improve visualisation. While the laser settings varied upon clinical situations, stone repositioning and extraction was used for clearance. They also advised patients on force fluid intake post-operatively to facilitate passage of small fragments. However, staged FURS was needed in larger stones and those in difficult locations, with an overall success rate of 88.2%. Atis et al. [15] described FURS in 20 patients with horseshoe kidneys. They performed a semirigid URS in all cases to initially dilate the ureter before placement of a UAS. They recommend stone relocation where possible and to use dusting setting (high frequency, low energy) for stone treatment. Failure was significantly higher in the lower pole and larger stones. Bozkurt et al. [16] investigated the outcomes in 26 patients with pelvic ectopic kidneys. Stone relocation and dusting method of stone treatment was used; however, a UAS was not used due to short tortuous ureter. Although the treatment was successful in 84.7%, it failed in patients with unfavourable infundibulopelvic anatomy. Oḡuz et al. [17] used FURS for treating kidney stones in 24 patients with isolated anomaly of kidney rotation, excluding HSK and EK. They used semirigid URS to passively dilate the ureter and placed a UAS in 83% of patients, with an initial and final SFR of 75% and 83.3%, respectively. Urgulu et al. [18] used FURS for stone disease in 25 patients with anomalous kidneys, including 1 patient with cross fused ectopia. They suggest the use of paediatric 9.5–11.5 F UAS in pelvic kidneys to overcome the difficulties of short tortuous ureters. The size of laser fibre and energy settings were determined intra-operatively according to stone size, location and composition. Ding et al. [19] reviewed the efficacy of FURS in 16 patients with HSK. Semirigid URS and UAS were used in all patients. Stone relocation was seen to increase the SFR as well as protecting the ureteroscope by minimising the duration of scope deflection. With six patients needing a repeat FURS, the initial and final SFR was 62.5% and 87.5%, respectively. Gokce et al. [20] compared the outcomes of SWL and FURS for treatment of stone disease in 67 patients with HSK, with similar patient and stone demographics between the groups. They recommend placing the patients in a slight Trendelenburg position to encourage stones to fall into upper calyces. They also used UAS, repositioned lower pole stones, used automatic flow irrigation at 100 cm H2O to improve visualisation and placed a ureteric stent as well as a urethral catheter in all patients to maximise drainage post-operatively. The SFR rate was significantly higher (p = 0.039) in the FURS group (73.9%) compared to the SWL group (47.7%) with no significant difference in complication rates between the groups. Bansal et al. [22] treated nine patients (12 renal units) with HSK and lower calyceal stones using FURS. They used UAS for all patients to optimise vision, keep a low intrarenal pressure and extract fragments. In cases where UAS placement was not possible, patients were stented and booked for a second planned procedure. With a stone dusting laser setting, the initial and final SFR was 67.7% and 88.7%, respectively. Ergin et al. [23] reported on 101 patients who underwent surgery for urolithiasis in anomalous kidneys over a 10-year period. Surgical techniques included FURS for stones less than 2 cm and PCNL for stones greater than 2 cm, or laparoscopic pyelolithotomy for large stones in ectopic kidneys. The overall SFR for HSK in the FURS group was 72.2% compared to 90% in the PCNL group; however, 14 patients in the PCNL group required a second procedure. In the EK group, FURS was compared to laparoscopic pyelolithotomy, although all stones in the laparoscopic pyelolithotomy group were in the renal pelvis (n = 9). The SFR rate for EK was 83.6% and 100% for FURS and laparoscopic pyelolithotomy, respectively. Finally, SFR for isolated rotational anomalies for FURS and PCNL was 75% and 83.3%, respectively. The overall SFR for FURS in all renal anomalies combined was 76.9%. Singh et al. [24] presented outcomes of FURS in 25 patients with various renal anomalies and stones < 2 cm. UAS and stone relocation to a favourable position was used in all patients. Laser settings were adjusted with dusting setting preferred for stone treatment. Patients were given an alpha blocker post-operatively and encouraged to increase their fluid intake to improve stone passage. Legemate et al. [25] reviewed data from the Clinical Research Office of the Endourological Society (CROES) URS Global Study and, of the 11,885 patients included, 86 patients were identified with anomalous kidneys that underwent URS for both renal and ureteric stones. The SFR for patients with and without pre-operative stent was 67% and 78%, respectively, and with and without UAS was 66% and 50%, respectively. Although the mean stone burden was highest in the EK group (120 mm2), the SFR for HSK, MR and EK groups was 77%, 71% and 20%, respectively. The SFR decreased in all three groups for patients in case the stone burdens were greater than 80 mm2. Astolfi et al. [26] collected prospective data on patients with anomalous kidneys undergoing FURS over a 6-year period and reported outcomes for 13 patients with an SFR of 75%. Semirigid ureteroscopy was performed initially and UAS use was preferred. Laser settings were adjusted according to stone location and composition with nitinol baskets used to relocate stones from unfavourable positions and to remove fragments. The anatomical variations of anomalous kidneys can lead to difficulties in either localising or accessing stones for treatment and therefore a higher complication rate may be expected compared to surgery for stones in normally formed kidneys [27]. Bas et al. [28] retrospectively analysed data on 1395 patients undergoing FURS for renal or proximal ureteric calculi and attempted to determine predictive factors affecting complication rates. On multivariate analysis, the only significant predictive factor was the presence of congenital renal abnormalities. The overall complication rate from the included studies was 17.2%. Out of these complications, only 2.4% were Clavien > III complications most of which related to re-intervention for ureteric colic. There was one Clavien IVa complication where a patient with urosepsis and acute renal failure received a nephrostomy and was transferred to the intensive care unit (ICU).

Tips and practical stepwise guidance for management from the included studies

Based on the included studies, there were certain tips and recommendations for ureteroscopy for stone disease in anomalous kidneys (Fig. 3). In a stepwise manner this included:
Fig. 3

Tips and practical guidance for management

Tips and practical guidance for management Performing a semirigid URS prior to FURS to passively dilate the ureter. Using a UAS if the ureteric anatomy allowed it and choosing a smaller length in pelvic kidneys. In EK, it should be adjusted to mid to lower ureter, or in a position such that the scope can flex in the pelvicalyceal system. Relocation of stones from an unfavourable to a more favourable position. Adjusting laser setting according to stone composition, but dusting seemed to be the preferred mode of stone treatment. Fragment retrieval and stone clearance to increase the SFR.

Comparison of URS with PCNL and SWL in management of stones in anomalous kidneys

The anatomical variation of anomalous kidneys presents technical challenges to access stones for treatment irrespective of the surgical technique undertaken [29]. Whilst SWL has the advantage of being non-invasive and avoids the need for general anaesthesia, stone localisation can be difficult due to the overlying bony structures or due to interposed bowel gas. The skin to stone distance is often increased and, even if SWL was successful in fragmenting the stone, impaired drainage can hinder the passage of the fragments, resulting in reduced SFR [27]. Ray et al. [6] reviewed the data of 41 patients with HSK undergoing SWL for renal stones. The success rate defined as being stone free or asymptomatic with residual fragments < 4 mm after single treatment was only 25%, increasing to 63.6% with additional treatments. They observed very little clinical benefit of offering more than two SWL sessions and multivariate analysis found stone burden, stone position and patient body mass index to be prognostic for SWL success. Sheir et al. [7] reported on their experience of SWL in 198 patients who were treated for a mean stone size of 13.54 mm (± 5.49). The overall SFR was 72.2% with 3.2% of patients who developed a steinstrasse. Tunc et al. [8] assessed the outcomes of 150 patients with anomalous kidneys and reported an overall SFR of 68% at 3 months. Stone size drove the success rate with SFR of 34% and 92% for stones > 30 mm and < 10 mm in size, respectively. PCNL offered higher stone clearance rates compared to SWL, but with a higher risk of associated complications. Due to the anatomical variations and abnormal relationship to the adjacent organs (especially bowel), there was an increased risk of iatrogenic injury during percutaneous access in PCNL, and access tracts were often longer. Abnormal vasculature was also common that must be considered in pre-operative planning [27]. Symons et al. [4] reviewed the 15-year outcomes of all patients who underwent surgical treatment for HSK. Of the 55 patients identified, the majority (85.5%) underwent PCNL, with an SFR of 77% after a single procedure. Tepeler et al. [3] analysed factors affecting outcomes of PCNL in 53 patients with HSK. For a mean stone size of 28.4 mm, the initial and final SFR was 66.7% and 90.7%, respectively. While auxiliary treatments increased SFR, the only factor affecting success rates on multivariate analysis was stone multiplicity.

Strengths, limitations and areas of future research

This systematic review comprehensively summarises the evidence for the role of URS in the setting of anomalous kidneys. Apart from the outcomes, it looks at tips and practical stepwise guidance provided from the included studies. Furthermore, the results can potentially set a benchmark for patient counselling and future research. The quality of included studies was poor with a high risk of bias and based mostly on small retrospective series; however, given the rarity of this condition, our review provides valuable insight, helps to condense the literature and might offer pitfalls and treatment strategies to endourologists. Although the reported complications in anomalous kidneys were higher, the rates of major complications were not different compared to URS in anatomically normal kidneys [30]. Future studies should also look at the cost comparison of the different treatment modalities [31-33]. A lack of standardised methods of data collection and reporting made it difficult to compare or combine the outcomes [34]. Retrograde intrarenal surgery is now being done for complex patients including those with morbid obesity, pregnancy and paediatric patients [35-37]. Improved training, flexible ureteroscopy technology and advances in laser have led to this procedure being successful in those with anomalous kidneys [38-40]. Patients with stone disease in anomalous kidneys need individualised management and probably should involve an interdisciplinary treatment with interventional radiology colleagues with interventions carried out in high volume endourology centres. Although randomised trials between treatment modalities would be difficult given the rarity of this condition, perhaps large prospective multi-centric studies with long-term follow-up and standardised references would be able to provide with high-quality insightful data.

Conclusion

Although URS in patients with anomalous kidneys can be technically challenging, advancements in endourological techniques have made it a safe and effective procedure. In these patients, the stone-free rates are good with a low risk of major complications.
  37 in total

1.  Surgical management of urinary stones with abnormal kidney anatomy.

Authors:  Giray Ergin; Mustafa Kirac; Ali Unsal; Burak Kopru; Mustafa Yordam; Hasan Biri
Journal:  Kaohsiung J Med Sci       Date:  2017-03-01       Impact factor: 2.744

2.  Retrograde intrarenal surgery in patients with horseshoe kidneys.

Authors:  Gokhan Atis; Berkan Resorlu; Cenk Gurbuz; Ozgur Arikan; Ekrem Ozyuvali; Ali Unsal; Turhan Caskurlu
Journal:  Urolithiasis       Date:  2012-12-21       Impact factor: 3.436

3.  Factors affecting complication rates of retrograde flexible ureterorenoscopy: analysis of 1571 procedures-a single-center experience.

Authors:  Okan Baş; Can Tuygun; Onur Dede; Sercan Sarı; Mehmet Çağlar Çakıcı; Ufuk Öztürk; Göksel Göktuğ; Abdurrahim İmamoğlu
Journal:  World J Urol       Date:  2016-09-07       Impact factor: 4.226

4.  Role of flexible uretero-renoscopy in management of renal calculi in anomalous kidneys: single-center experience.

Authors:  Abhishek Gajendra Singh; Jaspreet Singh Chhabra; Ravindra Sabnis; Arvind Ganpule; Ankush Jairath; Darshan Shah; Mahesh Desai
Journal:  World J Urol       Date:  2016-06-15       Impact factor: 4.226

Review 5.  Extracorporeal shock wave lithotripsy in anomalous kidneys: 11-year experience with two second-generation lithotripters.

Authors:  Khaled Z Sheir; Khaled Madbouly; Emad Elsobky; Mohamed Abdelkhalek
Journal:  Urology       Date:  2003-07       Impact factor: 2.649

6.  Ureteroscopic Urinary Stone Treatment Among Patients With Renal Anomalies: Patient Characteristics and Treatment Outcomes.

Authors:  Jaap D Legemate; Barbaros Baseskioglu; Jakub Dobruch; Jorge Gutierrez-Aceves; Oscar Negrete; Carlos Rioja Sanz; Muharrem Murat Yildiz; Jean J M C H de la Rosette
Journal:  Urology       Date:  2017-09-04       Impact factor: 2.649

7.  Flexible ureterorenoscopy in position or fusion anomaly: Is it feasible?

Authors:  Rafael Haddad Astolfi; Gustavo Freschi; Fernando Figueiredo Berti; Nelson Gattas; Wilson Rica Molina; Alex Meller
Journal:  Rev Assoc Med Bras (1992)       Date:  2017-08       Impact factor: 1.209

8.  Ureteroscopy is more cost effective than shock wave lithotripsy for stone treatment: systematic review and meta-analysis.

Authors:  Robert M Geraghty; Patrick Jones; Thomas R W Herrmann; Omar Aboumarzouk; Bhaskar K Somani
Journal:  World J Urol       Date:  2018-05-05       Impact factor: 4.226

9.  Flexible Ureteroscopic Management of Horseshoe Kidney Renal Calculi.

Authors:  Jie Ding; Yunteng Huang; Siping Gu; Yifan Chen; Jie Peng; Qiang Bai; Min Ye; Jun Qi
Journal:  Int Braz J Urol       Date:  2015 Jul-Aug       Impact factor: 1.541

Review 10.  Advances in Lasers for the Treatment of Stones-a Systematic Review.

Authors:  Peter Kronenberg; Bhaskar Somani
Journal:  Curr Urol Rep       Date:  2018-05-17       Impact factor: 3.092

View more
  2 in total

Review 1.  Is There Still a Place for Percutaneous Nephrolithotomy in Current Times?

Authors:  Elisa De Lorenzis; Stefano Paolo Zanetti; Luca Boeri; Emanuele Montanari
Journal:  J Clin Med       Date:  2022-08-31       Impact factor: 4.964

2.  Technique, Feasibility, Utility, Limitations, and Future Perspectives of a New Technique of Applying Direct In-Scope Suction to Improve Outcomes of Retrograde Intrarenal Surgery for Stones.

Authors:  Vineet Gauhar; Bhaskar Kumar Somani; Chin Tiong Heng; Vishesh Gauhar; Ben Hall Chew; Kemal Sarica; Jeremy Yuen-Chun Teoh; Daniele Castellani; Mohammed Saleem; Olivier Traxer
Journal:  J Clin Med       Date:  2022-09-27       Impact factor: 4.964

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.